Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012595 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2TRPV4ALDH1A1POLBTSHR | |
| SCHEMBL10800863 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2TRPV4ALDH1A1POLBTSHR | |
| SCHEMBL31650159 | 0.80 | SMN1; SMN2 (0.77) | SMN1; SMN2TRPV4ALDH1A1POLBTSHR | |
| SCHEMBL4188145 | 0.80 | SMN1; SMN2 (0.77) | SMN1; SMN2TRPV4ALDH1A1POLBTSHR | |
| SCHEMBL11440887 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2TRPV4POLBTSHRMAPK1 | |
| SCHEMBL1036692 | 0.78 | ALPL (0.52) | SMN1; SMN2TRPV4EPAS1ALDH1A1MAPK1 | |
| SCHEMBL28099031 | 0.78 | EPAS1 (0.65) | EPAS1POLBTSHRKMT2A | |
| SCHEMBL4239110 | 0.78 | ALDH1A1 (0.64) | EPAS1ALDH1A1POLBTSHRMAPK1 | |
| SCHEMBL4192386 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2TRPV4ALDH1A1POLBTSHR | |
| SCHEMBL15220366 | 0.75 | ALPL (0.51) | SMN1; SMN2TRPV4MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | SMN1; SMN2 1898/4885TRPV4 626/4885EPAS1 1098/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | SMN1; SMN2 1898/4885TRPV4 626/4885EPAS1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.